Page 264 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
JP20ck0106634 [to NS], JP17ck0106329 [to SA], JP20ck0106604 [to SA], and JP23ck0106853 [to DT]); the Project Promoting Clinical Trials for Development from AMED (grant number JP21lk0201702 [to ST]); Kawano Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics, a research grant from the Japanese Society of Hematology (to NS); and a research grant from the Takeda Science Foundation (to NS).
Data-sharing statement
Japan Children’s Cancer Group (JCCG) is committed to sharing, with
References
1. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease- directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-552.
2. Tomizawa D, Tawa A, Watanabe T, et al. Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia. 2013;27(12):2413-2416.
3. Tokumasu M, Murata C, Shimada A, et al. Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Leukemia. 2015;29(12):2438-2441.
4. Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48(12):1551-1556.
5. Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin- Frankfurt-Münster Study Group. J Clin Oncol. 2015;33(36):4247-4258.
6. Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30(29):3625-3632.
7. Segerink WH, Haas V de, Kaspers GJL. Measurable residual disease in pediatric acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther. 2021;21(4):451-459.
8. Shiba N, Yoshida K, Hara Y, et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019;3(20):3157-3169.
qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. The JCCG steering committee reviewed and approved these requests based on scientific merit. All data provided are anonymized to respect the privacy of patients who participated in the trial under applicable laws and regulations.
The results presented here were partly based on data generated by the TARGET dataset initiative, phs000218 (https://ocg.cancer.gov/ programs/target).
9. Chen X, Dou H, Wang X, et al. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. Leuk Lymphoma. 2017;59(4):829-836.
10. Christen F, Hoyer K, Yoshida K, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133(10):1140-1151.
11. Ishikawa Y, Group for the JALS, Kawashima N, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4(1):66-75.
12. Tomizawa D, Matsubayashi J, Iwamoto S, et al. High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia. Leukemia. 2024;38(1):202-206.
13. Shang L, Cai X, Sun W, Cheng Q, Mi Y. Time point‐dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21) (q22;q22.1). Cytom Part B Clin Cytom. 2022;102(1):34-43.
14. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021-3032.
15. Tarlock K, Alonzo TA, Wang Y-C, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res. 2019;25(16):5038-5048.
Haematologica | 110 January 2025
256